487 related articles for article (PubMed ID: 33761971)
1. Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy.
Lodewijk I; Nunes SP; Henrique R; Jerónimo C; Dueñas M; Paramio JM
Clin Epigenetics; 2021 Mar; 13(1):63. PubMed ID: 33761971
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
3. Leveraging epigenetics to enhance the efficacy of immunotherapy.
Licht JD; Bennett RL
Clin Epigenetics; 2021 May; 13(1):115. PubMed ID: 34001289
[TBL] [Abstract][Full Text] [Related]
4. The emerging role of epigenetic therapeutics in immuno-oncology.
Topper MJ; Vaz M; Marrone KA; Brahmer JR; Baylin SB
Nat Rev Clin Oncol; 2020 Feb; 17(2):75-90. PubMed ID: 31548600
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.
Dai E; Zhu Z; Wahed S; Qu Z; Storkus WJ; Guo ZS
Mol Cancer; 2021 Dec; 20(1):171. PubMed ID: 34930302
[TBL] [Abstract][Full Text] [Related]
6. Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy.
Liu M; Zhou J; Chen Z; Cheng AS
J Pathol; 2017 Jan; 241(1):10-24. PubMed ID: 27770445
[TBL] [Abstract][Full Text] [Related]
7. Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
Flower KJ; Ghaem-Maghami S; Brown R
Curr Cancer Drug Targets; 2018; 18(1):5-15. PubMed ID: 28176650
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Perspective of Immunotherapy for Cancers.
Keshari S; Barrodia P; Singh AK
Cells; 2023 Jan; 12(3):. PubMed ID: 36766706
[TBL] [Abstract][Full Text] [Related]
9. Cancer Epigenetics, Tumor Immunity, and Immunotherapy.
Cao J; Yan Q
Trends Cancer; 2020 Jul; 6(7):580-592. PubMed ID: 32610068
[TBL] [Abstract][Full Text] [Related]
10. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
[TBL] [Abstract][Full Text] [Related]
11. The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy.
Loo Yau H; Ettayebi I; De Carvalho DD
Trends Cell Biol; 2019 Jan; 29(1):31-43. PubMed ID: 30153961
[TBL] [Abstract][Full Text] [Related]
12. Targeting galectins in T cell-based immunotherapy within tumor microenvironment.
Jin QY; Li YS; Qiao XH; Yang JW; Guo XL
Life Sci; 2021 Jul; 277():119426. PubMed ID: 33785342
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy.
Maio M; Covre A; Fratta E; Di Giacomo AM; Taverna P; Natali PG; Coral S; Sigalotti L
Clin Cancer Res; 2015 Sep; 21(18):4040-7. PubMed ID: 26374074
[TBL] [Abstract][Full Text] [Related]
14. Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.
Pi YN; Qi WC; Xia BR; Lou G; Jin WL
Front Immunol; 2021; 12():697083. PubMed ID: 34295338
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
Maes K; Mondino A; Lasarte JJ; Agirre X; Vanderkerken K; Prosper F; Breckpot K
Front Immunol; 2021; 12():652160. PubMed ID: 33859645
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.
Yang J; Xu J; Wang W; Zhang B; Yu X; Shi S
Signal Transduct Target Ther; 2023 May; 8(1):210. PubMed ID: 37217462
[TBL] [Abstract][Full Text] [Related]
17. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.
Gnjatic S; Bronte V; Brunet LR; Butler MO; Disis ML; Galon J; Hakansson LG; Hanks BA; Karanikas V; Khleif SN; Kirkwood JM; Miller LD; Schendel DJ; Tanneau I; Wigginton JM; Butterfield LH
J Immunother Cancer; 2017; 5():44. PubMed ID: 28515944
[TBL] [Abstract][Full Text] [Related]
18. Turning Cold into Hot: Firing up the Tumor Microenvironment.
Duan Q; Zhang H; Zheng J; Zhang L
Trends Cancer; 2020 Jul; 6(7):605-618. PubMed ID: 32610070
[TBL] [Abstract][Full Text] [Related]
19. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
Xie G; Cheng T; Lin J; Zhang L; Zheng J; Liu Y; Xie G; Wang B; Yuan Y
J Immunother Cancer; 2018 Sep; 6(1):88. PubMed ID: 30208943
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.
Perrier A; Didelot A; Laurent-Puig P; Blons H; Garinet S
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
